Spondyloarthritis & psoriatic arthritis
Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024
An erratum to this article was published (J Rheumatol, 1 Nov 2025 ↗)
Study context
- Population
- Candidate composite outcome measures for psoriatic arthritis (PsA): Minimal disease activity (MDA), Disease Activity for Psoriatic Arthritis (DAPSA), American College of Rheumatology (ACR) response criteria, Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity Index (CPDAI), 3VAS and 4VAS
Methodological detailssystematic literature review in progress, OMERACT filter 2.2, Delphi exercise with patient research partners (ongoing), Updates presented by the GRAPPA-OMERACT PsA working group at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 annual meeting
- Systematic literature review in progress
- OMERACT filter 2.2
- Delphi exercise with patient research partners (ongoing)
- Updates presented by the GRAPPA-OMERACT PsA working group at the GRAPPA 2024 annual meeting
Main finding
As reported in the abstract
- Progress of a systematic literature review on psychometric properties of 7 candidate composite outcome measures (MDA, DAPSA, ACR, PASDAS, CPDAI, 3VAS, 4VAS) using OMERACT filter 2.2 presented
- Delphi exercise for patient research partners on domain match and feasibility ongoing; GRAPPA community endorsement to follow
- New research proposal: network meta-analysis to quantitatively compare responsiveness of these composite measures
Original publication
Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024. J Rheumatol. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →